[SCHEDULE 13G] MacroGenics, Inc. SEC Filing

Rhea-AI Filing Summary

On 07/07/2025, Bellevue Group AG and its wholly-owned subsidiary, Bellevue Asset Management AG, filed a Schedule 13G revealing a 9,929,963-share position in MacroGenics, Inc. (MGNX) as of 06/01/2025. The stake equals 15.7 % of the company’s outstanding common stock. Both entities are incorporated in Switzerland and report shared voting and dispositive power over the entire holding, with zero sole voting or dispositive authority. Bellevue is classified as a “HC, CO” (parent holding company/control person) and Bellevue Asset Management AG as “CO.”

The certification states that the shares were acquired and are held in the ordinary course of business and are not intended to influence control of MacroGenics. This filing increases transparency around MacroGenics’ ownership structure and highlights a sizeable passive investment from a regulated Swiss financial institution.

Positive

• Bellevue Group AG and Bellevue Asset Management AG now hold 9.93 million MacroGenics shares, representing a significant 15.7 % stake.

Negative

• None.

Insights

Equity Research Analyst

TL;DR: Swiss investor discloses passive 15.7 % stake, underscoring institutional confidence in MacroGenics.

The 13G filing shows Bellevue Group AG and its asset-management arm jointly owning nearly 10 million MacroGenics shares. Because the form is 13G, the position is declared passive, signalling no immediate activist intent. A 15.7 % holding materially lifts institutional ownership, which can support liquidity and potentially future capital raises. Shared, not sole, voting power confirms collaborative management of the stake within Bellevue’s entities. Overall impact skews positive by demonstrating significant third-party confidence without governance disruption.

Corporate Governance Expert

TL;DR: Large passive holding disclosed; governance impact minimal at present.

From a governance perspective, the filing satisfies regulatory transparency requirements once a holder exceeds the 5 % threshold. Because Bellevue filed Schedule 13G rather than 13D, it certifies a non-control intent, limiting near-term influence on board matters or strategic direction. Nonetheless, a single shareholder owning over 15 % concentrates voting power, which the board and other investors may monitor. No other control-related provisions are stated, maintaining a neutral governance stance.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

MacroGenics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

556099109

(CUSIP Number)

06/01/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 556099109

1

Names of Reporting Persons

Bellevue Group AG

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SWITZERLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 9,929,963.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 9,929,963.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

9,929,963.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

15.7 %

12

Type of Reporting Person (See Instructions)

HC, CO

SCHEDULE 13G

CUSIP No. 556099109

1

Names of Reporting Persons

Bellevue Asset Management AG

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SWITZERLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 9,929,963.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 9,929,963.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

9,929,963.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

15.7 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: MacroGenics, Inc.
(b)	Address of issuer's principal executive offices: 9704 Medical Center Drive Rockville, MD, 20850
Item 2.
(a)	Name of person filing: Bellevue Group AG ("Bellevue") on behalf of its wholly-owned subsidiary, Bellevue Asset Management AG ("BAM AG")
(b)	Address or principal business office or, if none, residence: Bellevue: Theaterstrasse 12, Zurich, Switzerland, CH-8001 BAM AG: Theaterstrasse 12, Zurich, Switzerland, CH-8001
(c)	Citizenship: Bellevue: Switzerland BAM AG: Switzerland
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 556099109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
	Swiss Financial Market Supervisory Authority (FINMA)
Item 4.	Ownership
(a)	Amount beneficially owned: 9,929,963
(b)	Percent of class: 15.7%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 9,929,963
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 9,929,963
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. This statement is filed jointly by Bellevue and BAM AG. BAM AG is a wholly-owned subsidiary of Bellevue.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Bellevue Group AG

Signature:	/s/ Stefano Montalbano
Name/Title:	Stefano Montalbano/ Chief Financial Officer
Date:	07/07/2025

Signature:	/s/ Christoph Eisenring
Name/Title:	Christoph Eisenring/ Head Legal & Compliance
Date:	07/07/2025

Bellevue Asset Management AG

Signature:	/s/ Christoph Eisenring
Name/Title:	Christoph Eisenring/ Head Legal & Compliance
Date:	07/07/2025

Signature:	/s/ Ivo Betschart
Name/Title:	Ivo Betschart/ Chief Finance & Controlling
Date:	07/07/2025

FAQ

How much of MacroGenics (MGNX) does Bellevue Group AG own?

Bellevue reports beneficial ownership of 15.7 % of MacroGenics’ outstanding common stock.

How many MacroGenics shares are owned by Bellevue?

The filing lists 9,929,963 shares held with shared voting and dispositive power.

Is the stake reported on a Schedule 13G or 13D?

The stake is disclosed on a Schedule 13G, indicating a passive investment.

Does Bellevue have sole or shared voting power over the shares?

Bellevue and its subsidiary report 0 sole and 9,929,963 shared voting rights.

When did the ownership threshold event occur?

The event triggering the filing is dated 06/01/2025.

Where are Bellevue Group AG and its asset management arm based?

Both entities are headquartered in Zurich, Switzerland.